Marten

Quick links to important sections

Marten

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Marten

Property Description
Active Ingredients Acetaminophen, Butalbital
Form Tablet, Capsule
Pharmacological Class Combination Analgesic, CNS Depressant
General Purpose Pain Relief and Relaxation
Origin Synthetic Derivatives

What Type of Drug is Marten, and What Does It Contain?

Marten is defined as a fixed-dose combination analgesic designed for oral administration, typically formulated as a tablet or capsule. It is classified as a synthetic prescription product that contains two distinct active ingredients: Acetaminophen and Butalbital. This specific formulation is distinguished from many common pain relievers because it combines two therapeutic agents with fundamentally different mechanisms.

From a pharmacological perspective, Marten belongs to the combination product class that couples a non-opioid pain reliever with a barbiturate derivative. Acetaminophen provides the primary analgesic action and is a p-aminophenol derivative. In contrast, Butalbital is a barbiturate derivative that functions as a Central Nervous System (CNS) Depressant. This classification reflects that the Butalbital component is an established sedative-hypnotic agent. This means the drug contains an ingredient that can slow down activity in the brain and nervous system, a feature not present in standard over-the-counter pain medications.

The Dual Action: How Does This Combination Help?

The overall purpose of Marten stems from its dual-action mechanism, providing both pain reduction and a general calming effect in a single formulation. The medication achieves this through the distinct actions of its components, addressing pain that is often accompanied by muscle tension or nervous stress, a common feature in specific types of discomfort.

The combination is engineered for a synergistic effect: the Acetaminophen component targets the physical sensation of pain, acting centrally to influence pain perception. Concurrently, the Butalbital component slows down brain activity to produce a sedative and relaxing action. The use of barbiturate combinations in managing pain that is complicated by tension supports the role of the CNS depressant component in the overall therapeutic approach. This confirms that the combination is formulated to address both the physical pain and the accompanying stress or tension, providing comprehensive relief where relaxation is required.

Regulatory References

  1. NIH Drug Information Portal

What side effects are possible with Marten?

Possible Side Effects and Safety Information

The safety profile of Marten is documented in regulatory sources based on adverse reaction frequency and affected organ systems. The profile highlights effects stemming from both the Central Nervous System (CNS) depressant component (Butalbital) and the analgesic component (Acetaminophen).

Adverse Reaction Scope

Category Officially Documented Details
Common Reactions Drowsiness, Lightheadedness, Dizziness, Sedation, Nausea, Vomiting, and Abdominal Pain.
Uncommon Reactions Flatulence, Mental Confusion, Depression, Anxiety, Nervousness, Excitement, Constipation, Shortness of Breath, and Tachycardia.
System-Organ Classes Primarily Nervous System Disorders and Gastrointestinal Disorders. Also includes Cardiac, Respiratory, and Skin disorders.
Serious Adverse Reactions Severe Hepatotoxicity (linked to Acetaminophen), Fatal Respiratory Depression (linked to Butalbital, especially in overdose), and serious Skin Reactions (e.g., Stevens-Johnson Syndrome).

Specific Safety Constraints

The regulatory labeling includes defined limitations and cautions for safe use:

  • Exposure-Related Pattern: Drug Dependence potential and the risk of Rebound Headaches are specifically associated with prolonged or chronic use of the product.
  • Population-Specific: The product is Contraindicated in individuals with severe Hepatic Impairment. Caution is also specified for Older Adults due to increased sensitivity to CNS depressant effects.
  • Co-Administration Risk: Explicit warnings detail the risk of Additive CNS Depression when used with other CNS depressants and the risk of Hepatotoxicity when used with other Acetaminophen-containing products.

The overall safety structure is defined by the mandates for addressing dependence potential and the constraints related to organ-specific toxicity.

Overdose and Emergency Response

Marten Overdose and When to Seek Help

Overdose scope Details based on Official Regulatory Documentation
Documented overdose presentations Initial manifestations may include nausea, vomiting, loss of appetite, and sweating. Later signs, particularly from the CNS depressant component, include severe drowsiness, confusion, tremor, and lightheadedness.
Physiological systems affected Primary systems affected are Hepatic function, leading to acute liver failure, and the Central Nervous System (CNS), causing severe respiratory depression and potential coma. Cardiovascular effects such as tachycardia are also documented.
Dose-related or exposure-related factors Ingestion of doses exceeding the maximum daily recommendation is associated with overdose risk, even in the absence of initial symptoms. Increased risk is noted for individuals who ingest alcohol or have underlying liver disease.
Emergency-response statements Seek immediate medical attention or call a poison control center immediately upon suspected excessive ingestion. Urgent medical evaluation is required if an excessive dose is taken, even if the individual reports feeling well.

Overdose Classifications (High-Level)

Classification Details based on Official Regulatory Documentation
Severity classification Overdose has the potential for life-threatening outcomes, including acute liver failure and severe respiratory depression.
Overdose-context constraints Management procedures described in regulatory documents include immediate blood testing to measure drug levels and the potential use of N-acetylcysteine as an antidotal agent for Acetaminophen toxicity.

Resulting Overdose Structure

Official overdose statements:

  • Acute liver failure, sometimes requiring a liver transplant or leading to death, is a potential outcome of the Acetaminophen component overdose.
  • Severe respiratory depression, hypovolemic shock, and coma are documented life-threatening events resulting from Butalbital component overdose.
  • Regulatory authorities mandate that individuals seek immediate medical attention following the ingestion of an excessive dose, regardless of the apparent presence of symptoms.

Connection to the overall overdose profile

Regulatory documents define this overdose profile based on the dual-system toxicity of its components, with one targeting the hepatic system and the other the CNS, which elevates the risk for life-threatening events like acute liver failure and severe respiratory depression. This necessitates the explicit regulatory mandate to seek immediate medical attention when an excessive dose has been ingested, regardless of initial symptoms.

Therapeutic Uses of Marten

What Marten Treats: Main Uses and Benefits

Marten is applied in addressing the acute symptom complex of tension headaches, which are often described as muscle contraction headaches. This combination is used in areas where short-term symptom management is appropriate for this symptomatic discomfort. The medication is commonly used across conditions characterized by episodic or fluctuating symptom patterns, particularly to help manage groups of symptoms that may become intense or disruptive.

The main therapeutic use of Marten is commonly used to help with managing symptom clusters that include head pain and accompanying nervous or muscular tension. The drug's supportive relief is relevant in contexts marked by increased discomfort and is typically applied during phases when symptoms become more noticeable. This approach offers supportive therapeutic benefit for patients whose discomfort is linked to increased physiological stress.

Quick Fact: Used for managing Tension Headaches and Muscular Discomfort

“The medication is relevant for easing symptoms that interfere with daily comfort and is used when a combination of pain relief and relaxation is needed.” This supportive relief contributes to improved comfort during periods where symptoms temporarily interfere with daily functioning. The overall intent is to support patients during difficult episodes by easing distress when the manifestation is acute.

Regulatory References

  1. NIH DailyMed resource

Eligibility and Restrictions for Use

Absolute Contraindications

Marten is contraindicated and must not be used in specific populations as defined by regulatory bodies. This includes patients with a known hypersensitivity or intolerance to Acetaminophen, Butalbital, or any other product component. It is also strictly contraindicated in patients with a diagnosis of porphyria.

Age and Organ Function Restrictions

The drug is officially established for use in adults and adolescents 12 years of age and older. Safety and effectiveness have not been established in children younger than 12 years. Caution is required when prescribing Marten for special-risk populations, including the elderly and patients with severe impairment of hepatic or renal function.

Conditions Requiring Caution

The label identifies conditions that increase risk and require clinical caution. Individuals with underlying liver disease or those who regularly ingest alcohol are at a higher risk of acute liver failure due to the Acetaminophen component. Use is restricted to a clear risk-benefit assessment during pregnancy and lactation, as the components are excreted into human milk.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Interactions with Marten (Acetaminophen and Butalbital combination) are officially documented, primarily focusing on two regulatory concerns: central nervous system (CNS) effects and liver toxicity.

Pharmacodynamic Interactions (CNS Depression)

Concomitant use with other CNS Depressants (including other barbiturates, narcotics, alcohol, sedatives, and tranquilizers) is associated with an additive or potentiated effect, which increases the risk of excessive CNS and respiratory depression. Alcohol (Ethanol) consumption also contributes to this risk.

Pharmacokinetic Interactions (Metabolism)

The Butalbital component, a barbiturate, is a known enzyme inducer. This can accelerate the metabolism of other medicinal products. It is also documented that enzyme induction may increase the formation of potentially hepatotoxic metabolites of the Acetaminophen component, especially with excessive alcohol consumption. Therefore, chronic, heavy consumption of alcohol increases the risk of serious acetaminophen-induced liver injury.

Specific Drug Classes and Restrictions

  • Monoamine Oxidase Inhibitors (MAOIs): Use is generally restricted or contraindicated, as MAOIs can prolong the effects of the Butalbital component.
  • Other Acetaminophen-Containing Products: Must be strictly avoided to prevent exceeding the maximum recommended daily dose and to mitigate the risk of hepatotoxicity.

The regulatory profile mandates close monitoring and often avoidance of these combinations, particularly in older or debilitated patients who may be more susceptible to the severe effects of CNS depression.

Mechanism of Action

Modulation of Platelet Activation and Aggregation

This domain focuses on the drug's action as an antagonist at the Thromboxane A2 ( TP) receptor and as an inhibitor of Phosphodiesterase type 3 ( PDE3) within platelets. By simultaneously blocking a pro-aggregation signal and elevating the internal messenger cyclic AMP ( cAMP), the mechanism results in a reduced tendency for platelets to aggregate, influencing the characteristics of blood flow.


Targeted Regulation of Vascular Smooth Muscle Tone

Marten's second core mechanism involves the inhibition of Phosphodiesterase type 5 ( PDE5), which is concentrated in the walls of small blood vessels. This action preserves and elevates the levels of the critical messenger cyclic GMP ( cGMP), triggering relaxation of the vascular smooth muscle. The physiological consequence of this signaling cascade is vasodilation, which physically reduces resistance within the vasculature.

Dosage and Administration Information

How to Use Marten: Administration Guidelines

Administration of Marten (Acetaminophen and Butalbital) must strictly follow procedural and quantitative guidelines to ensure proper usage.


Dosing and Frequency

Administration Detail Labeled Instruction
Route of Administration The medication is for oral use, available as tablets, capsules, and oral solutions.
Standard Dosing 1 to 2 dosage units per administration, taken every 4 hours as needed.
Total Daily Limits The total dose should generally not exceed 6 dosage units per 24 hours. The intake of Acetaminophen from all sources must be strictly limited to 4000 mg per day.

Use Patterns and Special Considerations

Specific constraints are established on the duration and method of use:

  • Duration: The extended or repeated use of this product is not recommended. Use is restricted to the shortest duration consistent with the necessary use protocol.
  • Discontinuation: If the medicine has been taken regularly and physical dependency is present, the dose must be tapered gradually to discontinue use.
  • Timing/Food: The medicine may be taken with or without food. For optimal administration, it is often taken at the first signs of discomfort.
  • Population Rules: For older adults, dose selection requires caution and should typically start at the low end of the dosing range. Safety and efficacy are not established for children under 12 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase I: Initial Investigations

Initial research focused on how the compound behaved in the body and its potential molecular interactions. Small-scale studies examined patient health status, recording data on symptoms reported by participants over the study period.

These early investigations primarily aimed to assess how the body processed the compound (pharmacokinetics) and to establish a preliminary safety profile in healthy volunteers.

Phase II: Dose-Finding and Exploration

Studies in the second phase were randomized and placebo-controlled. Researchers sought to determine the optimal dose range and explore the correlation between the compound and specific clinical endpoints.

Study protocols included close participant monitoring; the research design specified that the compound was not studied concurrently with Drug-X. The Phase II findings supported the initiation of the large-scale investigation that followed.

Phase III: Large-Scale Clinical Trials

Large-scale clinical trials have since focused on examining the relationship between this medication and recorded shifts in pain levels, particularly during acute episodes. These trials included thousands of participants across multiple centers. The studies compared the effects of the investigational compound against both a placebo and a currently available treatment (Drug-Y).

The primary focus of these studies was a change in the patient-reported pain score over a three-month period. The findings of these studies are currently under review; the combination therapy was compared against other standard treatments in long-term management.

Sub-Group Analysis and Long-Term Follow-Up

An additional phase III trial evaluated the compound's potential effects on patient health status and examined its use in patients over 65. The study protocols required long-term follow-up to track changes in patient status and record any potential long-term adverse events. The findings from this sub-group analysis and the long-term observational study are still being integrated into the larger body of evidence.

Frequently Asked Questions (FAQ)

Common questions about Marten (FAQ)

Q: What is the main reason Marten is prescribed?

According to official product information, Marten is approved for the relief of the symptom complex associated with tension headaches, also known as muscle contraction headaches. Its formulation is described as having dual action, addressing both the physical sensation of pain and the accompanying tension or stress.

Q: Does Marten interact with blood pressure medicine?

The Butalbital component of Marten is described in regulatory documents as an enzyme inducer. This means it may potentially speed up the metabolism of other medications, including drugs used for blood pressure, if they are primarily processed by the liver. Official guidance notes that caution is necessary with any drug that is extensively metabolized in this way.

Q: What if I miss a day of taking Marten?

This medicine is generally taken as needed, not on a daily schedule. If a scheduled dose is missed, regulatory sources describe taking it as soon as it is remembered. Official instructions indicate that patients should not take extra medicine or double up to compensate for a missed dose.

Q: Is Marten a controlled substance?

Yes, due to the presence of Butalbital, Marten is classified by the U.S. Drug Enforcement Administration (DEA) as a Schedule III controlled substance. This classification reflects the potential for dependence and abuse associated with the barbiturate component.

Q: Why is Marten only available by prescription?

Its prescription status is primarily due to the Butalbital component, which is a barbiturate with potential for abuse, dependence, and serious side effects. The regulatory status requires the medication to be used under professional supervision.

Q: Can Marten make an existing condition worse?

Regulatory documents list specific contraindications, meaning conditions where the drug must not be used. For example, Marten is contraindicated in patients with porphyria (a blood disorder) and severe hepatic impairment (severe liver damage). The drug is not recommended for use in these conditions due to the potential for the underlying condition to worsen.

Q: Does Marten have an antidote?

While the Butalbital component does not have a specific antidote, the treatment for a potential Acetaminophen overdose includes the administration of an established agent called N-acetylcysteine.

Q: Does Marten have a 'black box' warning?

Yes, the official labeling includes an FDA Boxed Warning. This warning specifically alerts patients and prescribers to the risk of hepatotoxicity (severe liver damage) associated with the Acetaminophen component.

Q: Do people develop a tolerance to Marten over time?

Regulatory documents explicitly state that both tolerance and physical or psychological dependence can develop when using this product. This risk is particularly associated with prolonged or chronic use of Marten.

Q: Can Marten affect my ability to drive?

Official information includes a specific warning that Marten may impair the mental and/or physical abilities required for potentially hazardous tasks. Official information indicates that tasks like driving a car or operating heavy machinery should be avoided until an individual knows how the medication affects them.

Q: Is Marten safe for people with kidney problems?

Regulatory information indicates the need for caution in patients who have severe renal impairment (severe kidney problems). This is because the body primarily eliminates the Butalbital component through the kidneys.

Q: What is the expected long-term effect of Marten?

Official labeling states that the extended or repeated use of Marten is not recommended by regulatory agencies. This recommendation is based on the risk of developing medication overuse headaches (rebound headaches) and the potential for drug dependence associated with chronic use.

Q: Does Marten interact with common over-the-counter pain relievers?

Official warnings indicate the need to avoid taking Marten with any other product that contains Acetaminophen. This is to avoid exceeding the maximum recommended daily dose and mitigate the serious risk of liver injury.

How should Marten be stored and disposed of?

Official Storage and Disposal Instructions

Regulatory labeling for Marten (Acetaminophen and Butalbital) specifies precise requirements for storage and discarding the product.

Storage Conditions

Marten must be stored at Controlled Room Temperature (CRT), maintained between 20 C to 25 C (68 F to 77 F). The medication must be kept in a tight and light-resistant container to ensure stability. The container used for dispensing is required to comply with CPSC child-resistant standards and must always be stored out of reach of children.

Disposal Requirements

Unused or expired Marten should be disposed of primarily through an authorized drug take-back program. If this is not possible, the official instruction is to mix the product with an undesirable substance (such as cat litter or used coffee grounds) and place the mixture in a sealed container for disposal in the household trash. The product must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Marten found in:

A-Z Index: